Prostate Blood Tests: PSA, Free PSA & Screening Guide
Prostate cancer is the most commonly diagnosed cancer in Australian men. Understanding PSA testing — what it measures, what it misses, and when it's genuinely useful — helps you make informed decisions with your GP.
Who Should Consider PSA Testing?
PSA testing is not recommended as a blanket screening test for all men. The Prostate Cancer Foundation of Australia (PCFA) and the Royal Australian College of General Practitioners (RACGP) both emphasise informed decision-making rather than routine screening. However, certain groups benefit more from testing:
Average Risk
Men aged 50–69 should discuss PSA testing with their GP. A baseline PSA at 50 helps establish a personal reference point. If baseline is below 1.0 µg/L, the risk of clinically significant prostate cancer within 10 years is very low, and less frequent testing (every 2–4 years) may be appropriate.
Higher Risk
Men with a first-degree relative (father or brother) diagnosed with prostate cancer should start discussions at age 40–45. Men of African ancestry have approximately double the risk. BRCA2 gene carriers have a 2–5 fold increased risk and should consider annual testing from age 40. Aboriginal and Torres Strait Islander men may benefit from earlier screening.
Understanding PSA Blood Tests
Total PSA (Prostate-Specific Antigen)
What it measures: PSA is a protein produced exclusively by prostate cells. It is present in small amounts in the blood of all men with a prostate. PSA is prostate-specific but NOT cancer-specific — any condition that affects the prostate can elevate PSA, including benign prostatic hyperplasia (BPH), prostatitis, urinary tract infections, recent ejaculation, vigorous exercise, and prostate cancer. PSA testing has been available since the late 1980s and remains the most widely used prostate screening tool, despite ongoing debate about its effectiveness as a population-wide screening test.
Normal ranges: Age-specific ranges (RCPA): Under 50: below 2.5 µg/L. 50–59: below 3.5 µg/L. 60–69: below 4.5 µg/L. 70–79: below 6.5 µg/L. The traditional threshold of 4.0 µg/L is increasingly considered oversimplified. PSA velocity (rate of rise over time) may be more informative than a single reading — a rise of more than 0.75 µg/L per year warrants investigation even if the absolute value is within range.
Elevated in: Benign prostatic hyperplasia (BPH, the most common cause of mildly elevated PSA), prostatitis (can cause very high PSA, often above 10 µg/L), urinary tract infection, recent ejaculation (within 48 hours), vigorous cycling or digital rectal exam (DRE), prostate cancer (typically gradual rise over months to years), and medications including 5-alpha reductase inhibitors (finasteride, dutasteride) which halve PSA — multiply the result by 2 if taking these drugs.
Limitations: PSA has a high false-positive rate: approximately 75% of men with PSA between 4–10 µg/L do NOT have prostate cancer on biopsy. Conversely, approximately 15% of men with PSA below 4.0 µg/L DO have prostate cancer. This means PSA can both over-detect (leading to unnecessary biopsies) and under-detect. A single elevated PSA should always be repeated before further investigation, ideally after 4–6 weeks.
Free PSA and Free-to-Total PSA Ratio
What it measures: PSA circulates in two forms: bound to proteins (complexed PSA) and unbound (free PSA). In prostate cancer, a greater proportion of PSA is bound, resulting in a lower percentage of free PSA. The free-to-total PSA ratio helps distinguish BPH from cancer when total PSA falls in the diagnostic grey zone (4–10 µg/L). This test is ordered as a reflex test when total PSA is in the grey zone, not as an initial screening tool.
Normal ranges: Free/Total ratio above 25%: low risk of cancer (suggests BPH). Ratio 15–25%: intermediate risk. Ratio below 15%: higher risk of cancer — further investigation usually recommended. Below 10%: significantly increased risk. These cutoffs are approximate and vary by laboratory and patient age.
Elevated in: A high free PSA ratio (above 25%) is typically seen in BPH, where benign prostate tissue produces more free PSA. A low free PSA ratio (below 15%) is more suggestive of prostate cancer, where malignant tissue produces more complexed PSA. However, prostatitis can also alter the ratio unpredictably.
Limitations: The free PSA ratio is only useful when total PSA is in the grey zone (4–10 µg/L). Outside this range, the ratio adds little diagnostic value. Free PSA is unstable and degrades at room temperature — blood samples must be processed within 3 hours. Finasteride and dutasteride reduce both total and free PSA proportionally, so the ratio remains valid in men taking these medications.
PSA Density and PSA Velocity
What it measures: PSA density divides the total PSA by the prostate volume (measured by ultrasound or MRI), accounting for the fact that larger prostates naturally produce more PSA. PSA velocity tracks the rate of PSA change over time — serial measurements 12–18 months apart. PSA doubling time calculates how quickly PSA is doubling, which is particularly relevant after treatment for prostate cancer to detect recurrence.
Normal ranges: PSA density: below 0.15 µg/L/cc is reassuring. Above 0.15 suggests possible cancer warranting further investigation. PSA velocity: a rise of more than 0.75 µg/L per year is concerning regardless of absolute PSA level. PSA doubling time: less than 3 months after treatment suggests aggressive recurrence.
Elevated in: High PSA density: prostate cancer (small gland, high PSA). High PSA velocity: aggressive prostate cancer, acute prostatitis (transient spike). Short PSA doubling time: recurrent or metastatic prostate cancer post-treatment.
Limitations: PSA density requires imaging to measure prostate volume, adding cost and complexity. PSA velocity requires at least 3 measurements over 18–24 months to be reliable — a single measurement is insufficient. Acute prostatitis can cause rapid PSA spikes that mimic high velocity, so timing of measurements matters.
BPH vs Prostatitis vs Prostate Cancer
An elevated PSA does not mean cancer. In fact, the most common cause of PSA elevation is benign prostatic hyperplasia (BPH), an age-related enlargement of the prostate that affects over 50% of men by age 60. Understanding the differences helps you interpret results with your GP.
| Feature | BPH | Prostatitis | Cancer |
|---|---|---|---|
| Typical PSA level | 4–10 µg/L (proportional to size) | Can be very high (>20 µg/L) | Any level (often 4–20 µg/L) |
| Free PSA ratio | High (>25%) | Variable | Low (<15%) |
| PSA velocity | Slow, stable rise | Sudden spike, then falls | Gradual, persistent rise |
| Onset | Gradual over years | Acute or subacute | Usually asymptomatic |
| Urinary symptoms | Frequency, hesitancy, weak stream | Pain, burning, urgency | Often none until advanced |
| DRE finding | Enlarged, smooth, rubbery | Tender, boggy | Hard nodule or asymmetry |
| Age group | Very common after 50 | Any age (peaks 30–50) | Rare before 50, peaks 65–80 |
The PSA Screening Debate: Arguments For and Against
PSA screening is one of the most debated topics in preventive medicine. There is genuine disagreement among experts, and understanding both sides helps you have a productive conversation with your GP.
In favour of screening
Early detection of aggressive cancers (Gleason 7+) when treatment is most effective. 20% reduction in prostate cancer mortality in the European ERSPC trial. Allows active surveillance for low-risk cancers instead of immediate treatment.
Source: ERSPC trial, Prostate Cancer Foundation of Australia (PCFA)Against routine screening
High false-positive rate (75% of elevated PSAs are not cancer). Over-diagnosis of clinically insignificant cancers that would never cause harm. Unnecessary biopsies with risk of infection and complications. No mortality benefit in the US PLCO trial (though crossover contamination criticised).
Source: PLCO trial, RACGP GuidelinesCurrent Australian position
The RACGP does NOT recommend routine PSA screening for asymptomatic men. Instead, GPs should provide informed decision-making: explain benefits AND harms, then respect the patient’s choice. PCFA recommends baseline PSA at age 50 (or 40–45 if higher risk). MBS Item 66655 covers PSA for screening; Item 66659 covers PSA for monitoring known prostate disease.
Source: RACGP Red Book (2024), PCFA Guidelines, MBS OnlineWhat Happens After an Abnormal PSA Result
An elevated PSA triggers a stepwise investigation. Your GP will NOT immediately recommend a biopsy. The typical pathway in Australia follows these steps:
Repeat PSA in 4–6 weeks (confirm the elevation is real, not transient)
Free PSA ratio if total PSA is 4–10 µg/L (helps stratify risk)
Digital rectal exam (DRE) to feel for nodules or asymmetry
Multiparametric MRI (mpMRI) of the prostate — now recommended BEFORE biopsy
MRI-guided or TRUS biopsy if MRI shows PI-RADS 3–5 lesions
Urology referral for PSA above 10 µg/L or suspicious DRE/MRI findings
Active surveillance if low-risk cancer detected (Gleason 6, small volume)
Testosterone levels may be checked — low testosterone can mask PSA elevation
Testosterone and Prostate Health
Testosterone has a complex relationship with the prostate. Prostate cancer is androgen-dependent — it requires testosterone to grow — which is why androgen deprivation therapy (ADT) is a mainstay of advanced prostate cancer treatment. However, the outdated belief that testosterone replacement therapy (TRT) causes prostate cancer has been largely debunked.
Current evidence suggests that TRT does not increase the risk of developing prostate cancer in men with normal prostate function. However, it is contraindicated in men with active or untreated prostate cancer. Men on TRT should have PSA monitored every 3\u20136 months for the first year and annually thereafter. A PSA rise of more than 1.4 \u00b5g/L in the first 12 months of TRT warrants investigation.
The relationship between 5-alpha reductase inhibitors (finasteride, dutasteride) and PSA is clinically important. These medications, used for BPH and hair loss, halve PSA levels within 6\u201312 months. Your GP must multiply the PSA result by 2 to get the "true" value. Failure to adjust for this medication effect can mask a rising PSA.
Related Reading
Track Your PSA Levels Over Time
Upload your blood test results and our AI will graph your PSA trends, calculate velocity, and flag concerning changes — free and private.
Reference ranges sourced from the Royal College of Pathologists of Australasia (RCPA) and the Prostate Cancer Foundation of Australia (PCFA). SmarterBlood provides health information and AI-powered blood test analysis. It is not a substitute for professional medical advice, diagnosis, or treatment.